No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ACIU AC Immune
- 2.350
- +0.060+2.62%
Close Apr 26 16:00 ET
232.41MMarket Cap-3347P/E (TTM)
2.495High2.250Low107.79KVolume2.300Open2.290Pre Close254.97KTurnover0.24%Turnover RatioLossP/E (Static)98.90MShares5.14052wk High1.32P/B104.77MFloat Cap1.78052wk Low--Dividend TTM44.58MShs Float19.970Historical High--Div YieldTTM10.71%Amplitude1.680Historical Low2.365Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Calendar of U.S. Earnings Expected in the Week Ahead
Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc. Company Symbo
CALM,PLAY and VNDA Are Among After Hour Movers
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)
Express News | HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target
AC Immune Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/15/2024 380.48% HC Wainwright & Co. → $16 Reiterates Buy → Buy 11/13/2023 380.48% HC Wainwright & Co. →
Buy Rating for AC Immune SA on Promising Alzheimer's Vaccine Trial Design and Potential Accelerated Approval
Comments
Ph2 readouts in Q1 2024...
$Pfizer(PFE.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$Vera Therapeutics(VERA.US$ Phase 2b
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$Akero Therapeutics(AKRO.US$ Phase 2b
$Spruce Biosciences(SPRB.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Annexon(ANNX.US$ Phase 2a
$Roivant Sciences(ROIV.US$...
$Leap Therapeutics(LPTX.US$ Phase 2
$Vera Therapeutics(VERA.US$ Phase 2b
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$Akero Therapeutics(AKRO.US$ Phase 2b
$Spruce Biosciences(SPRB.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Annexon(ANNX.US$ Phase 2a
$Roivant Sciences(ROIV.US$...
23
Upcoming Ph 2 readouts in Q1 2024…
$Cellectar BioSciences(CLRB.US$ Phase 2
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2...
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2...
36
6
Update
$AC Immune(ACIU.US$ Press Release: AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances Into Phase 2b Trial
Dow Jones· 5 mins ago
Dow Jones· 5 mins ago
good news
$AC Immune(ACIU.US$
so if you read the news it states that they are granting them more time based on information that RNAZ has given them.. so imo that would mean they are granting more time basewd on good news they are on the brink of something good just need a little time to fine tune!! just my opionion not advice.
so if you read the news it states that they are granting them more time based on information that RNAZ has given them.. so imo that would mean they are granting more time basewd on good news they are on the brink of something good just need a little time to fine tune!! just my opionion not advice.
News
$AC Immune(ACIU.US$ AC Immune Says Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential As Neurodegenerative Disease Diagnostic
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg